These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1961306)

  • 21. [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].
    Ito M; Mochizuki T; Koike T; Hashimoto N; Fukazawa S; Akatsuka T; Niida Y; Tozawa S; Yasuda T; Sato M
    Clin Calcium; 2005 Sep; 15 Suppl 1():11-13; discussion 13-4. PubMed ID: 16279016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
    Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
    Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of six disorders of calcium and phosphorus metabolism.
    Henneman PH
    Mod Treat; 1968 Jul; 5(4):676-83. PubMed ID: 5670900
    [No Abstract]   [Full Text] [Related]  

  • 25. The role of magnesium binders in chronic kidney disease.
    Spiegel DM
    Semin Dial; 2007; 20(4):333-6. PubMed ID: 17635824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of oral administration of calcium carbonate, aluminum hydroxide gel and dihydrotachysterol on renal acidosis.
    Ueda H; Ikeda H; Sasaki Y; Shioji R
    Tohoku J Exp Med; 1978 Jan; 124(1):1-11. PubMed ID: 635890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium and phosphorus metabolism in patients who have chronic kidney disease.
    Goodman WG
    Med Clin North Am; 2005 May; 89(3):631-47. PubMed ID: 15755471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which therapy to prevent post-thyroidectomy hypocalcemia?
    Pisaniello D; Parmeggiani D; Piatto A; Avenia N; d'Ajello M; Monacelli M; Calzolari F; Sanguinetti A; Parmeggiani U; Sperlongano P
    G Chir; 2005 Oct; 26(10):357-61. PubMed ID: 16371185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term dialysis and its problems: calcium and phosphorus metabolism disorders, aluminum balance, and esteodystrophy].
    Kurokawa K
    Nihon Rinsho; 1980 Jun; 38(6):2329-36. PubMed ID: 6997567
    [No Abstract]   [Full Text] [Related]  

  • 31. [Altered calcium-phosphorus metabolism and low-protein diet].
    Santoro D; Cianciaruso B
    G Ital Nefrol; 2008; 25 Suppl 42():S25-8. PubMed ID: 18828130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Calcium needs in hemodialyzed-parathyroidectomized patients].
    Zahiri K; Hachim K; Fatihi el M; Benghanem MG; Ramdani B; Zaïd D
    Ann Med Interne (Paris); 2002 Nov; 153(7):433-9. PubMed ID: 12598828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach.
    Novak JE; Szczech LA
    Semin Dial; 2009; 22(1):56-63. PubMed ID: 19000107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphate binders: hold the calcium?
    Bushinsky DA
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):695-6. PubMed ID: 17699274
    [No Abstract]   [Full Text] [Related]  

  • 36. Introduction to sevelamer hydrochloride and its clinical effects.
    Tahara H; Tsujimoto Y; Shoji T; Inaba M; Tabata T; Nishizawa Y
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S2-6. PubMed ID: 16109137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments in the management of hyperphosphatemia in chronic kidney disease.
    McIntyre CW
    Semin Dial; 2007; 20(4):337-41. PubMed ID: 17635825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic options for mineral metabolism disorders in dialysis patients: a case report].
    Cozzolino M; Pasho S; Missaglia E; Crovetto C; Fallabrino G; Brancaccio D
    G Ital Nefrol; 2008; 25(2):234-7. PubMed ID: 18350504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The metabolic acidosis of chronic renal failure: pathophysiology and treatment.
    Giovannetti S; Cupisti A; Barsotti G
    Contrib Nephrol; 1992; 100():48-57. PubMed ID: 1458909
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of hyperphosphatemia in chronic renal failure].
    Babarykin DA; Afanas'eva GA; Shul'man OM; Luse LIa; Rozental' RL
    Ter Arkh; 1984; 56(7):64-6. PubMed ID: 6484838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.